Renal Replacement Therapy for Cardiogenic Shock

(OFFLOAD-SHOCK Trial)

HF
Overseen ByHannah Feagan, RN
Age: 18+
Sex: Any
Trial Phase: Phase 4
Sponsor: Ottawa Heart Institute Research Corporation
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

CAPITAL OFFLOAD-SHOCK will aim to answer if early use of renal replacement therapy, like dialysis, in patients with reduced body fluids causing the heart to be unable to pump enough blood through the body reduces in-hospital death when compared to the current standard of care. The current standard of care is to wait until renal replacement therapy is clinically necessary.

Who Is on the Research Team?

SP

Simon Parlow, MD, FRCPC

Principal Investigator

Ottawa Heart Institute Research Corporation

Are You a Good Fit for This Trial?

Inclusion Criteria

I am 18 or older and have been admitted to an intensive care unit.
I have signs or symptoms of fluid overload in my body.
I have been diagnosed with severe cardiogenic shock (SCAI Class C or D).

Exclusion Criteria

Severe metabolic acidosis with serum bicarbonate 12 mmol/L or lower at the time of screening
Hyperkalemia with serum potassium 6 mmol/L or higher at the time of screening
Severe azotemia with serum urea 40 mmol/L or higher at the time of screening
See 6 more

What Are the Treatments Tested in This Trial?

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Active Control

Group I: Immediate Renal Replacement TherapyExperimental Treatment1 Intervention
Group II: Standard Medical TreatmentActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Ottawa Heart Institute Research Corporation

Lead Sponsor

Trials
200
Recruited
95,800+